Volume 35, 8 Oktober 2004 | 10/2004 |
SPOT ON | |
ANGELIQ (estradiol plus drospirenone) for "hormone replacement therapy" | |
QUALITY ASSESSMENT | |
Quality of captopril (e.g. LOPIRIN) products | |
NEW ON THE MARKET | |
COX-2 inhibitor etoricoxib (ARCOXIA) | |
THERAPIES FROM A CRITICAL VIEW POINT | |
Ximelagatran (EXANTA): licensing in USA uncertain | |
a-t READERS' QUESTIONS AND COMMENTS | |
Cinnamon (DIABETRUW) for diabetes mellitus? | |
IN BRIEF | |
Vitamins without benefit in cancer prevention | |
CURRENT ADR NETWORK REPORT | |
Severe myopathy with long-acting nicotinic acid (NIASPAN) | |
WITHDRAWAL FROM THE MARKET | |
Rofecoxib (VIOXX) phased out worldwide because of cardiovascular toxicity | |
© arznei-telegramm 10/2004 | ||